NVIC

Moderna COVID-19 Vaccine Clinical Trial Data in Infants and Young Children\r\n

Published November 10, 2021

In June 2022, the FDA authorized use of a 25mcg Moderna COVID-19 mRNA vaccine in infants and children ages six months through five years, to be given as a 2-dose series. According to the FDA, the most common adverse events reported after vaccination in clinical trials included redness, swelling, and pain at the injection site, fever and underarm (or groin) tenderness and swelling of lymph nodes in the same arm or leg as the injection. In children aged 37 months through five years, the most common adverse events included headache, muscle ache, joint stiffness, fatigue, chills, nausea and vomiting. Among children ages six through 36 months of age, the most commonly reported side effects also included loss of appetite, irritability and crying, and sleepiness.  

Adverse events of clinical significance reported among children aged two through five-years who received the vaccine included erythema multiforme, seizure, chest pain, food allergy (egg), urticaria, rash, conjunctivitis, anaphylaxis, seizure, dyspnea, mental status change, chest pain, metapneumovirus, rhinovirus infection, adenovirus infection, Epstein-Barr virus infection, viral pneumonia, urinary tract infection, bronchial hyperactivity, and humerus fracture. In children aged six through 23 months, additional adverse events that occurred during clinical trials included a diagnosis of Type 1 diabetes, pyrexia with febrile seizure, metapneumovirus infection, rhinovirus infection, mastoiditis, erythema multiforme, electrolyte imbalance, bronchiolitis, febrile convulsion, adenovirus infection, asthma, croup infection, viral gastroenteritis, and cough with wheezing and urticaria.

Select disease / vaccine